Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors.

Last updated on 10-1-2023 by Dominique Pierre

Peer reviewed scientific article




BACKGROUND: Patients with cancer, especially hematological cancer, are at increased risk for breakthrough COVID-19 infection. So far, a predictive biomarker that can assess compromised vaccine-induced anti-SARS-CoV-2 immunity in cancer patients has not been proposed. METHODS: We employed machine learning approaches to identify a biomarker signature based on blood cytokines, chemokines, and immune- and non-immune-related growth factors linked to vaccine immunogenicity in 199 cancer patients receiving the BNT162b2 vaccine. RESULTS: C-reactive protein (general marker of inflammation), in…

Associated health topics:

QR code

QR code for this page URL